What's Happening?
After more than a decade of global consultation, polycystic ovary syndrome (PCOS) has been renamed to polyendocrine metabolic ovarian syndrome (PMOS). This change was announced at the European Congress of Endocrinology in Prague, following collaboration
between international societies and patient groups. The renaming aims to address the misleading nature of the term 'polycystic', which has contributed to delayed diagnosis and inadequate medical care. The new name reflects the condition's complex nature, affecting not only the reproductive system but also metabolism and the risk of diabetes and cardiovascular disease. The initiative was led by endocrinologist Prof. Helena Teede, who emphasized the importance of patient perspectives in the renaming process.
Why It's Important?
The renaming of PCOS to PMOS is significant as it aims to improve understanding and treatment of the condition, which affects one in eight women globally. The previous name often led to misconceptions, focusing primarily on ovarian cysts rather than the broader hormonal and metabolic issues involved. This change is expected to enhance medical care by promoting a more comprehensive approach to diagnosis and treatment, potentially reducing the stigma and confusion associated with the condition. By acknowledging the multi-system impact of PMOS, healthcare providers can offer more effective management strategies, improving the quality of life for millions of women.
What's Next?
The new name will be fully implemented in the next update to international guidelines for managing the condition, expected by 2028. This transition period will involve educating healthcare professionals and the public about the change to ensure widespread adoption. The initiative also highlights the importance of patient involvement in medical decision-making, setting a precedent for future healthcare reforms. As awareness grows, it is anticipated that research and funding for PMOS will increase, leading to better diagnostic tools and treatment options.
